N4 Pharma PLC Investor Presentation
02 Outubro 2023 - 3:00AM
RNS Non-Regulatory
TIDMN4P
N4 Pharma PLC
02 October 2023
Reach - Non-Regulatory
2 October 2023
N4 Pharma Plc
("N4 Pharma" or the "Company")
Investor Presentation
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce that an updated investor
presentation ("Presentation") incorporating the Company's
acquisition of a 71% interest in Nanogencis Limited is now
available on the N4 Pharma website. To view a copy of the
Presentation, please click here:
http://www.rns-pdf.londonstockexchange.com/rns/2596O_1-2023-10-1.pdf
Enquiries:
N4 Pharma Plc Via IFC Advisory
Nigel Theobald, CEO
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: + 44 (0)20 3470
Nominated Adviser and Joint Broker 0470
Matthew Johnson/Kasia Brzozowska (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
Turner Pope Investments (TPI) Limited Tel: +44 (0)20 3657
Joint Broker 0050
Andy Thacker
IFC Advisory Limited
Financial PR Tel: +44 (0)20 3934
Graham Herring 6630
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre-clinical and clinical programs, N4
Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFIFSDITLLIIV
(END) Dow Jones Newswires
October 02, 2023 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024